Yorktown Management & Research Company’s Genmab GMAB Stock Holding History

Yorktown Management & Research Company’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,600	Closed	-$529K	–	228
2023 Q4	$529K	Hold	16,600	–	–	0.55%	55
2023 Q3	$585K	Hold	16,600	–	–	0.66%	36
2023 Q2	$631K	Hold	16,600	–	–	0.68%	39
2023 Q1	$627K	Hold	16,600	–	–	0.68%	36
2022 Q4	$704K	Buy	16,600 +6,500	+64%	+$268K	0.86%	21
2022 Q3	$325K	Hold	10,100	–	–	0.42%	94
2022 Q2	$328K	Hold	10,100	–	–	0.42%	105
2022 Q1	$365K	Hold	10,100	–	–	0.31%	134
2021 Q4	$400K	Hold	10,100	–	–	0.27%	149
2021 Q3	$441K	Hold	10,100	–	–	0.33%	125
2021 Q2	$412K	Hold	10,100	–	–	0.32%	134
2021 Q1	$332K	Buy	10,100 +4,500	+80%	+$169K	0.28%	130
2020 Q4	$228K	Buy	+5,600	New	+$209K	0.21%	212

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Yorktown Management & Research Company's GMAB Position: Q1 2024 in Review

Yorktown Management & Research Company sold out of Genmab (GMAB) in Q1 2024, closing a stake of 16,600 shares — an estimated $529K sold.

Yorktown Management & Research Company first reported a position in GMAB in Q4 2020 and held it in 13 quarters. The position peaked at $704K in Q4 2022. 228 funds tracked by Wall St. Rank hold GMAB as of Q1 2024.

Yorktown Management & Research Company reported no remaining Genmab position as of Q1 2024 after selling out during the quarter.
Yorktown Management & Research Company sold 16,600 Genmab shares in Q1 2024, an estimated $529K.
Yorktown Management & Research Company first reported a position in Genmab in Q4 2020 and held it in 13 quarters.
Yorktown Management & Research Company's Genmab position peaked at $704K in Q4 2022.
228 funds tracked by Wall St. Rank held Genmab as of Q1 2024.

Based on Yorktown Management & Research Company's 13F filing for Q1 2024, filed 26 Apr 2024.